Invivyd Inc (IVVD)

$4.17

-0.11

(-2.57%)

Market is closed - opens 8 PM, 29 Feb 2024

Performance

  • $4.12
    $4.35
    $4.17
    downward going graph

    1.2%

    Downside

    Day's Volatility :5.22%

    Upside

    4.07%

    downward going graph
  • $0.98
    $5.20
    $4.17
    downward going graph

    76.49%

    Downside

    52 Weeks Volatility :81.15%

    Upside

    19.81%

    downward going graph

Returns

PeriodInvivyd IncIndex (Russel 2000)
3 Months
177.92%
0.0%
6 Months
136.46%
0.0%
1 Year
145.98%
-6.7%
3 Years
-79.5%
-19.6%

Highlights

Market Capitalization
515.8M
Book Value
$2.24
Earnings Per Share (EPS)
-1.55
Wall Street Target Price
7.67
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-28.74%
Return On Equity TTM
-54.35%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-160.5M
Diluted Eps TTM
-1.55
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.56
EPS Estimate Next Year
-1.41
EPS Estimate Current Quarter
-0.5
EPS Estimate Next Quarter
-0.55

Analyst Recommendation

Sell
    11%Buy
    44%Hold
    44%Sell
Based on 9 Wall street analysts offering stock ratings for Invivyd Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
1
1
1
Hold
4
4
4
Sell
4
4
4

Analyst Forecast

What analysts predicted

Upside of 83.93%

Current $4.17
Target $7.67

Technicals Summary

Sell

Neutral

Buy

Invivyd Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Invivyd Inc
Invivyd Inc
-14.74%
136.46%
145.98%
-79.5%
-79.5%
Moderna, Inc.
Moderna, Inc.
-8.24%
-15.49%
-30.7%
-38.88%
325.66%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.93%
19.55%
30.63%
114.52%
130.61%
Novo Nordisk A/s
Novo Nordisk A/s
12.12%
30.39%
73.39%
235.66%
399.41%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-1.12%
22.56%
48.44%
104.83%
128.3%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Invivyd Inc
Invivyd Inc
NA
NA
NA
-1.56
-0.54
-0.29
NA
2.24
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.94
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.21
28.21
2.0
44.85
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
45.17
45.17
4.45
3.31
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.25
31.25
0.59
16.74
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Invivyd Inc
Invivyd Inc
Sell
$515.8M
-79.5%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$35.9B
325.66%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$107.8B
130.61%
28.21
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$544.3B
399.41%
45.17
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$112.0B
128.3%
31.25
36.68%

Institutional Holdings

  • M28 Capital Management LP

    8.42%
  • FMR Inc

    7.34%
  • Alphabet Inc

    5.17%
  • Orbimed Advisors, LLC

    4.80%
  • Maverick Capital Ltd

    4.80%
  • 683 Capital Management LLC

    3.64%

Company Information

adagio is developing best-in-class antibodies that can broadly neutralize sars-cov-2, sars-cov-1 and additional potentially emergent coronaviruses. we believe our antibodies will match or exceed the potency and coverage of conventional sars-cov-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments. our candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. our portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. our lead program is expected to enter the clinic by the end of 2020.

Organization
Invivyd Inc
Employees
84
CEO
Mr. David Hering M.B.A.
Industry
Services

FAQs